Viewpoint Molecular Targeting, Inc. announced it has entered into a Memorandum of Understanding with The National Nuclear Laboratory to explore avenues to supply Pb-212 to researchers, and possibly clinicians, in the United Kingdom and Europe, using Viewpoint’s proprietary isotope generator, VMT-
- Viewpoint is focused on solidifying a global [212Pb] supply strategy through relationship building from research through commercialization
- Agreement significantly expands Company’s network of researchers and clinicians in the UK and Europe
CORALVILLE, IA / ACCESSWIRE / November 16, 2021 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into a Memorandum of Understanding (MoU) with The National Nuclear Laboratory (NNL) to explore avenues to supply Pb-212 to researchers, and possibly clinicians, in the United Kingdom and Europe, using Viewpoint’s proprietary isotope generator, VMT-